AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6137857 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 16
Study 6137857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30586223 — intervention group
Group type: EXPERIMENTAL
Intervention: Training materials including expert eye gaze
Number of subjects: 21
Study 30586223 — intervention group
Group type: COMPARATOR
Intervention: Training materials without expert eye gaze
Number of subjects: 21
Study 26261865 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term combination programme (CP) comprising short-term day-hospital treatment followed by outpatient combined group and individual psychotherapy
Number of subjects: 52
Study 26261865 — intervention group
Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy (OIP)
Number of subjects: 52
Study 26030319 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 85
Study 26030319 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (job club approach with peer support)
Number of subjects: 85
Study 26030319 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 85
Study 26030319 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 85
Study 22865153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (BWL, n = 23)
Number of subjects: 39
Study 22865153 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL, n = 16)
Number of subjects: 39
Study 20499131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2ME2 NanoCrystal® dispersion (NCD) at 1,500 mg orally four times daily, repeated in 28 day cycles
Number of subjects: 21
Study 20499131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2ME2 NanoCrystal® dispersion (NCD)
Number of subjects: 21
Study 20137600 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 415
Study 20137600 — intervention group
Group type: COMPARATOR
Intervention: High tibial osteotomy (HTO)
Number of subjects: 415
Study 16670385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 1031
Study 15277317 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/d for 6 months
Number of subjects: 30
Study 15277317 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 30
Study 11896110 — intervention group
Group type: COMPARATOR
Intervention: CT (cisplatin and dacarbazine every 21 days)
Number of subjects: 176
Study 11896110 — intervention group
Group type: EXPERIMENTAL
Intervention: bioCT (CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN alpha-2b three times a week for six cycles)
Number of subjects: 176
Study 9869892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) therapy
Number of subjects: 0
Study 9869892 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine treatment
Number of subjects: 0
Study 9869892 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 8560289 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional folic acid supplementation
Number of subjects: 0
Study 2283644 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 173
Study 2283644 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 173
Study 378017 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 2
Study 378017 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (0.004 mg/kg)
Number of subjects: 2
Study 6342838 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 1884
Study 6342838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study 30945664 — intervention group
Group type: EXPERIMENTAL
Intervention: MdHOXs under cold treatment
Number of subjects: 207
Study 30945664 — intervention group
Group type: EXPERIMENTAL
Intervention: MdHOXs under osmotic treatment
Number of subjects: 207
Study 30945664 — intervention group
Group type: EXPERIMENTAL
Intervention: MdHOXs under high salinity treatment
Number of subjects: 207
Study 30945664 — intervention group
Group type: EXPERIMENTAL
Intervention: MdHOXs under exogenous ABA treatment
Number of subjects: 207
Study 29676530 — intervention group
Group type: EXPERIMENTAL
Intervention: lorcaserin
Number of subjects: 137
Study 29676530 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study 27349906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (self-management program)
Number of subjects: 174
Study 27349906 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control program)
Number of subjects: 174
Study 25424121 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (4 g/day intravenous)
Number of subjects: 30
Study 22876543 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (PAM), 1 mg/kg/day over 2 days
Number of subjects: 23
Study 22876543 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL), 0.025-0.05 mg/kg/day over 2 days every 3-4 months
Number of subjects: 23
Study 22876543 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (PAM)
Number of subjects: 23
Study 22876543 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 23
Study 20460412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed health or appearance messages for individuals high in body consciousness
Number of subjects: 390
Study 20460412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed health or appearance messages for individuals low in body consciousness
Number of subjects: 390
Study 20460412 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 390
Study 20460412 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific message framing)
Number of subjects: 390
Study 18820247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-magnesium (bolus of magnesium 50 mg epidurally before induction, followed by infusion of 10 mg h(‐1) until end of surgery)
Number of subjects: 90
Study 18820247 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-magnesium (epidural saline during the same time periods plus bolus epidural magnesium 50 mg at the end of surgery)
Number of subjects: 90
Study 18820247 — intervention group
Group type: COMPARATOR
Intervention: Control (epidural saline during all three periods)
Number of subjects: 90
Study 15661415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel laparotomy
Number of subjects: 69
Study 15661415 — intervention group
Group type: COMPARATOR
Intervention: Vertical laparotomy
Number of subjects: 69
Study 12423847 — intervention group
Group type: EXPERIMENTAL
Intervention: Water soluble lubricant
Number of subjects: 182
Study 12423847 — intervention group
Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 182
Study 10514160 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of 20 mg methylprednisolone plus lignocaine
Number of subjects: 164
Study 10514160 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for two weeks
Number of subjects: 164
Study 10514160 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 164
Study 7671364 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of digoxin (0.39 +/- 0.11 mg/day)
Number of subjects: 22
Study 7671364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1866609 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofunctional dentin adhesive without linings
Number of subjects: 77
Study 1866609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifunctional dentin adhesive without linings
Number of subjects: 77
Study 1866609 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofunctional dentin adhesive with linings
Number of subjects: 77
Study 1866609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifunctional dentin adhesive with linings
Number of subjects: 77
Study 1866609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifunctional dentin adhesive 'Prisma Universal Bond 2'
Number of subjects: 77
Study 1866609 — intervention group
Group type: COMPARATOR
Intervention: In-vitro specimens (control group)
Number of subjects: 77
Study 7009103 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundnut oil or safflower oil
Number of subjects: 0
Study 7009103 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA rich oil
Number of subjects: 0
Study 7009103 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0
Study 31393600 — intervention group
Group type: EXPERIMENTAL
Intervention: Chairside bacterial test (CST)
Number of subjects: 125
Study 31393600 — intervention group
Group type: COMPARATOR
Intervention: Quantitative polymerase chain reaction (qPCR)
Number of subjects: 125
Study 30554466 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Gr B) for 12 weeks
Number of subjects: 50
Study 30554466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Gr A) for 12 weeks
Number of subjects: 50
Study 28732491 — intervention group
Group type: EXPERIMENTAL
Intervention: Job retention vocational rehabilitation (VR)
Number of subjects: 55
Study 28732491 — intervention group
Group type: COMPARATOR
Intervention: Written advice only (control)
Number of subjects: 55
Study 25785683 — intervention group
Group type: EXPERIMENTAL
Intervention: Local dexamethasone and lidocaine infiltration (Group DL)
Number of subjects: 160
Study 25785683 — intervention group
Group type: COMPARATOR
Intervention: Local lidocaine infiltration (Group L)
Number of subjects: 160
Study 24780643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (60 g)
Number of subjects: 12
Study 24780643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (30 g)
Number of subjects: 12
Study 24780643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (60 g)
Number of subjects: 12
Study 24780643 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (60 g)
Number of subjects: 12
Study 24780643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (60 g) and (30 g)
Number of subjects: 12
Study 23071214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (addition of 1 hour of sleep relative to baseline habitual sleep duration on weekdays)
Number of subjects: 34
Study 23071214 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction (elimination of 1 hour of sleep relative to baseline habitual sleep duration on weekdays)
Number of subjects: 34
Study 19226471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once-daily for 12 weeks
Number of subjects: 987
Study 19226471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 987
Study 19226471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Number of subjects: 987
Study 17327446 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 112
Study 17327446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 15295223 — intervention group
Group type: EXPERIMENTAL
Intervention: PncCRM vaccine
Number of subjects: 1490
Study 15295223 — intervention group
Group type: COMPARATOR
Intervention: Control (hepatitis B vaccine)
Number of subjects: 1490
Study 11266237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer therapy
Number of subjects: 37
Study 11266237 — intervention group
Group type: COMPARATOR
Intervention: High-dose inhaler therapy
Number of subjects: 37
Study 10440656 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle
Number of subjects: 995
Study 10440656 — intervention group
Group type: COMPARATOR
Intervention: Toronto SPV
Number of subjects: 995
Study 7929770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid bacterial identification and antimicrobial susceptibility testing (same-day procedure)
Number of subjects: 573
Study 7929770 — intervention group
Group type: COMPARATOR
Intervention: Traditional overnight techniques for bacterial identification and antimicrobial susceptibility testing
Number of subjects: 573
Study 3075178 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (daily 100 MRC of salmon calcitonin intramuscularly)
Number of subjects: 110
Study 3075178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (daily 1000 mg orally)
Number of subjects: 110
Study 3075178 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (De‐Nol - four times a day in doses of 5 ml diluted with 15 ml of water)
Number of subjects: 110
Study 27691376 — intervention group
Group type: EXPERIMENTAL
Intervention: MOMCare (choice of brief interpersonal psychotherapy, pharmacotherapy, or both)
Number of subjects: 160
Study 27691376 — intervention group
Group type: COMPARATOR
Intervention: MSS-Plus (intensive maternity support services)
Number of subjects: 160
Study 25293524 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg droperidol
Number of subjects: 75
Study 25293524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 75
Study 25293524 — intervention group
Group type: COMPARATOR
Intervention: 8 mg ondansetron
Number of subjects: 75
Study 23703789 — intervention group
Group type: EXPERIMENTAL
Intervention: Y90 without Sorafenib (Group A)
Number of subjects: 15
Study 23703789 — intervention group
Group type: EXPERIMENTAL
Intervention: Y90 with Sorafenib (Group B)
Number of subjects: 15
Study 21361982 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB + regret first
Number of subjects: 576
Study 21361982 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB + regret mixed
Number of subjects: 576
Study 21361982 — intervention group
Group type: COMPARATOR
Intervention: TPB only
Number of subjects: 576
Study 19703317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group
Number of subjects: 26
Study 19703317 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 16440422 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole o.d.
Number of subjects: 36
Study 16440422 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole b.i.d.
Number of subjects: 36
Study 16440422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (30 mg lansoprazole o.d. and 30 mg lansoprazole b.i.d.)
Number of subjects: 36
Study 15359680 — intervention group
Group type: EXPERIMENTAL
Intervention: EID interface with maximally adequate instrumentation
Number of subjects: 0
Study 15359680 — intervention group
Group type: EXPERIMENTAL
Intervention: EID interface with minimally adequate instrumentation
Number of subjects: 0
Study 15359680 — intervention group
Group type: COMPARATOR
Intervention: PID interface with minimally adequate instrumentation
Number of subjects: 0
Study 11151743 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin aglycone (8 mg, 20 mg, 50 mg)
Number of subjects: 16
Study 11151743 — intervention group
Group type: COMPARATOR
Intervention: Rutin (8 mg, 20 mg, 50 mg)
Number of subjects: 16
Study 9380609 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g of piracetam combined with cognitive therapy
Number of subjects: 162
Study 9380609 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g of piracetam combined with cognitive therapy
Number of subjects: 162
Study 9380609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 8269741 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (segmentectomy, bisegmentectomy, enucleation) with controlled hypotension and temporary occlusion of the hepatoduodenal ligament
Number of subjects: 721
Study 8269741 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sonography and determination of alpha-fetoprotein for early detection of HCC
Number of subjects: 721
Study 3903821 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-8-vasopressin (LVP) for 10 days, up to 13.5 LVP units
Number of subjects: 12
Study 3903821 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-8-vasopressin (LVP)
Number of subjects: 12
Study 31607119 — intervention group
Group type: EXPERIMENTAL
Intervention: STET model for estimating PM1 concentrations
Number of subjects: 0
Study 31607119 — intervention group
Group type: EXPERIMENTAL
Intervention: STET model
Number of subjects: 0
Study 29742587 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (25 mg/kg) and N-acetylcysteine (140 mg/kg)
Number of subjects: 12
Study 29742587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27108746 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 40
Study 27108746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23721352 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session sex education lesson on chlamydia
Number of subjects: 0
Study 23721352 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching on STIs
Number of subjects: 0
Study 21431376 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 31
Study 21431376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing TKA
Number of subjects: 31
Study 21431376 — intervention group
Group type: COMPARATOR
Intervention: Natural knee joints
Number of subjects: 31
Study 21431376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TKA designs
Number of subjects: 31
Study 19549743 — intervention group
Group type: EXPERIMENTAL
Intervention: GHR antagonist (pegvisomant, 10 mg/d)
Number of subjects: 20
Study 19549743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17825688 — intervention group
Group type: COMPARATOR
Intervention: Epoetin delta 15 IU/kg IV tiw for 4 weeks
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 40 IU/kg IV tiw for 4 weeks
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 100 IU/kg IV tiw for 4 weeks
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 75 IU/kg IV
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 75 IU/kg SC
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 50 IU/kg tiw for 4 weeks
Number of subjects: 121
Study 17825688 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 50 IU/kg tiw for 4 weeks
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 100 IU/kg tiw for 4 weeks
Number of subjects: 121
Study 17825688 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 100 IU/kg tiw for 4 weeks
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 150 IU/kg IV
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 300 IU/kg IV
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 150 IU/kg SC
Number of subjects: 121
Study 17825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 300 IU/kg SC
Number of subjects: 121
Study 14984181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (50 microg/ml)
Number of subjects: 10
Study 14984181 — intervention group
Group type: COMPARATOR
Intervention: Oxygen autohemotherapy
Number of subjects: 10
Study 11158813 — intervention group
Group type: EXPERIMENTAL
Intervention: I(125) brachytherapy
Number of subjects: 623
Study 8141635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis educational and support program (HESP)
Number of subjects: 0
Study 8141635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2971473 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril
Number of subjects: 16
Study 29880069 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU
Number of subjects: 84
Study 29880069 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%)
Number of subjects: 84
Study 28760246 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC 0.4/5 mg
Number of subjects: 510
Study 28760246 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg
Number of subjects: 510
Study 28760246 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC 0.2/5 mg
Number of subjects: 510
Study 26018348 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free de novo immunosuppressive treatment (mycofenolate mofetil, steroids, basiliximab) with delayed introduction of sirolimus
Number of subjects: 27
Study 23549975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 86
Study 23549975 — intervention group
Group type: COMPARATOR
Intervention: Control (watchful waiting)
Number of subjects: 86
Study 21471671 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg/day
Number of subjects: 199
Study 21471671 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day
Number of subjects: 199
Study 19031934 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe (grade 3 or 4) hematological toxicity during chemotherapy
Number of subjects: 475
Study 19031934 — intervention group
Group type: COMPARATOR
Intervention: No severe myelotoxicity during chemotherapy
Number of subjects: 475
Study 16877071 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone Ahmed Glaucoma Valve
Number of subjects: 132
Study 16877071 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene Ahmed Glaucoma Valve
Number of subjects: 132
Study 15189632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexism condition
Number of subjects: 0
Study 15189632 — intervention group
Group type: COMPARATOR
Intervention: Personal deservingness condition
Number of subjects: 0
Study 15189632 — intervention group
Group type: EXPERIMENTAL
Intervention: Discounting rejection (blaming it on discrimination)
Number of subjects: 0
Study 15189632 — intervention group
Group type: EXPERIMENTAL
Intervention: Discounting rejection
Number of subjects: 0
Study 10634823 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol supplementation (50 mg daily)
Number of subjects: 28519
Study 10634823 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene supplementation (20 mg daily)
Number of subjects: 28519
Study 10634823 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28519
Study 9436798 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe cystic PVL
Number of subjects: 66